Cargando…

Clinical investigation into the initial diagnosis and treatment of 539 patients with stage IV lung cancer

OBJECTIVE: The aim of the study was to analyze clinical data, including the types of pathologic classification, metastatic organs, treatment strategy, and prognosis of patients with stage IV lung cancer. METHODS: A retrospective analysis of the clinical features of 539 patients with stage IV lung ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Qian, Liu, Shanshan, Wang, Wei, Zhang, Yingjie, Li, Fengxiang, Li, Jianbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5293499/
https://www.ncbi.nlm.nih.gov/pubmed/28203086
http://dx.doi.org/10.2147/OTT.S125108
Descripción
Sumario:OBJECTIVE: The aim of the study was to analyze clinical data, including the types of pathologic classification, metastatic organs, treatment strategy, and prognosis of patients with stage IV lung cancer. METHODS: A retrospective analysis of the clinical features of 539 patients with stage IV lung cancer who were initially diagnosed and treated in 2009 was conducted. There were 146 cases of single organ metastases and 393 cases of multiple organ metastases. The Kaplan-Meier method and multivariate Cox regression analysis were performed to analyze the influence of age, pathological classification, metastatic organs, and treatment strategy on overall survival. RESULTS: The 1-, 2-, and 3-year survival rates were 64.2% (n=346), 19.7% (n=106), and 1.5% (n=8), respectively. Metastases to the liver and pleura predicted poor prognosis, although bone metastases predicted relatively good prognosis. The prognosis of single brain metastasis was relatively better than that of multiple brain metastases. Multi-factor analysis showed that the patient’s age, different metastatic organs, the numbers of metastatic organs, and different treatment were independent risk factors for survival. CONCLUSION: The prognosis for patients with stage IV lung cancer is poor. Patient’s age, the type and number of metastatic organs, and method of treatment are the main factors affecting survival.